Sorafenib-associated Trichodysplasia Spinulosa versus Follicular Hyperkeratosis: a case report
Reem Hasan, Nemat Alsaghir, Kinda Alshawa, Sajeda Alnabelsi, Hanaa Almsokar · 2025
Read Sorafenib-associated Trichodysplasia Spinulosa versus Follicular Hyperkeratosis: a case report by Reem Hasan, Nemat Alsaghir, Kinda Alshawa, Sajeda Alnabelsi, Hanaa Almsokar (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12741442.txt.
Description
Reem Hasan and co-authors report a spiky skin eruption in a patient taking the cancer drug sorafenib, in a 2025 case report. Sorafenib blocks several growth signals and treats advanced cancers such as liver cancer, but it often troubles the skin. The eruption matched trichodysplasia spinulosa, a rare condition of hair follicles usually tied to immune suppression, and never before pinned on this drug.
The close rival diagnosis was follicular hyperkeratosis, a plugging of follicles with keratin. The team lays out how the two differ and weighs which fits. They propose the drug scrambles keratin building in the skin, a risk sharpened in immunosuppressed patients. The report adds a face to watch for in clinics.
Catalog record
| CREATOR | Reem Hasan, Nemat Alsaghir, Kinda Alshawa, Sajeda Alnabelsi, Hanaa Almsokar |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |